Virus
Human coronavirus 229E, HCoV-229E
Strain/Type
Genus: Alphacoronavirus (previously group 1)
Source/Company
Charité Universitaetsmedizin Berlin, Christian Drosten
Usage Regulation and Limitations
Obey the usage regulations listed in the MTA including that the virus can only be used for the reseach project listed in the MTA and it is not for use in anaimal experiments:
View file | ||||
---|---|---|---|---|
|
How to cite
Refer for publications to the rules listed in the MTA including that the Charité need to be informed 4 weeks prior to a publication and the Chharité and Christian Drosten need to be either co-author or acknowledged:
View file | ||||
---|---|---|---|---|
|
Host tropism
HumansRoute of Transmission
Infection can be transmitted through inhalation of respiratory droplet aerosols; virus can also be spread via the fecal-oral route, and through fomites
Zoonosis (transmission between animals and humans): No
Characteristics e.g. sensitizing or toxic effects, replication deficiant, not infectious, attenuated, inactivated (upload relevant documents)
Human-pathogenic (causes diseases in humans).
HCoV-229E and HCoV-OC43 cause the common cold, a self-limiting upper respiratory tract infection. Infection can lead to a number of illnesses such as bronchitis, gastroenteritis, progressive demyelinating encephalitis, diarrhea, peritonitis, nasal obstruction, rhinorrhea, sneezing, sore throat and cough. They can cause more severe lower respiratory tract infection, including pneumonia in infants, elderly and immunocompromised individuals. HCoV-229E is a common agent if coryza, whereas HCoV-OC43 is generally characterized by sore throats. HCoV-NL63 causes laryngotracheitis (croup) and nonfatal upper and lower respiratory tract infections in children, elderly, and immunocompromised individuals. HCoV-HKU1 causes mild upper respiratory diseases, the common cold, bronchiolitis, and pneumonia, with symptoms such as rhinorrhoea, fever, cough, febrile seizure, and wheezing. More severe illness may occur in children, adults with underlying disease, the elderly, and may be associated with gastrointestinal illness.
Approved as biological safety measure if taken as recipient organism for genetic engineering?
Genetically modified (GenTSV)
Risk group (BioStoffV)
2
Risk assessment
Risk accessment based on TRBA (Technical Rule for Biological Agents) 462 "Classification of viruses into risk groups": https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Regelwerk/TRBA/TRBA-462.html
Operation instructions (mandatory for RG2 and higher)
https://biostoffe.dguv.de/data?name=830377&lang=en
View file | ||||
---|---|---|---|---|
|
View file | ||||
---|---|---|---|---|
|
Occupational health care (according to ArbMedVV)
Optional health care:
In the case of tasks specifically involving contact and tasks involving incidental contact with biological agents classed as Risk Group 2 under the Biological Agents Ordinance (Biostoffverordnung, BioStoffV) or which involve a comparable risk, the employer must offer an optional health care. This does not apply when on account of the risk assessment and on account of the protective measures taken it can be assumed that there is no risk of infection.
An optional health care must also be offered if as a result of the exposure to biological agents
- a serious infectious illness is to be expected and post-exposure prophylatic measures are possible, or
- an infection has resulted.
Vaccination:
None available.
Storage location of aliquots in the Biolab (just click Bearbeiten in the right corner of the header to add or change information in the table and use the menue in the left header to e.g. add a row)
source | virus strain | freezing date | virus amount per vial | stock was produced on | no. of aliquots | belongs to (full name) | rack/box in N2 tank or -80°C freezer and location (room, address) | comments |
---|---|---|---|---|---|---|---|---|
Charité Universitaetsmedizin Berlin, Christian Drosten | 229E | Huh-7 | Katharina Achazi/Chuanxiong Nie | -80 pi | in preparation | |||